Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS

American Journal of Clinical Pathology

Volumn 127, Issue 1, 2007, Pages 89-96

  Gomes, Ana L ^a   Bardales, Ricardo H ^b,e   Milanezi, Fernanda ^a,c   Reis, Rui M ^a   Schmitt, Fernando ^a,c,d  

^a UNIVERSITY OF MINHO   (Portugal)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PORTO   (Portugal)

^d University of Porto   (Portugal)

^e Outpatient Pathology Associates   (United States)

Author keywords

c Kit; Endoscopic ultrasound guided fine needle aspiration; Gastrointestinal stromal tumor; GIST; Mutations; PDGFRA; Platelet derived growth factor

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ARTICLE; ASPIRATION BIOPSY; CONTROLLED STUDY; DNA ISOLATION; EXON; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MESENCHYMOMA; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; ADULT; AGED; AMINO ACID SEQUENCE; CHEMISTRY; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; FEMALE; GENETICS; MALE; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; BASE SEQUENCE; BIOPSY, FINE-NEEDLE; ENDOSONOGRAPHY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 34249077294     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/M1EC8JE9ACAMJACU     Document Type: Article

References (42)

1. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology. 2006;48:83-96.
2. Joensuu H, Kindblom LG. Gastrointestinal stromal tumors: a review. Acta Orthop Scand Suppl. 2004;75:62-71.
3. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002;160:1567-1572.
4. Monihan JM, Carr NJ, Sobin LH. CD34 immunoexpression in stromal tumours of the gastrointestinal tract and in mesenteric fibromatoses. Histopathology. 1994;25:469-473.
5. Miettinen M, Virolainen M, Maarit SR. Gastrointestinal stromal tumors: value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol. 1995;19:207-216.
6. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
7. Hirota S. Gastrointestinal stromal tumors: their origin and cause. Int J Clin Oncol. 2001;6:1-5.
8. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004;61:2924-2931.
9. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004;61:2535-2548.
10. Roskoski R Jr. Structure and regulation of Kit protein-tyrosine kinase: the stem cell factor receptor. Biochem Biophys Res Commun. 2005;338:1307-1315.
11. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 1998;29:498-504.
12. Looijenga LH, de Leeuw H, van Oorschot M, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res. 2003;63:7674-7678.
13. Rossi G, Cavazza A, Marchioni A, et al. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol. 2003;16:1041-1047.
14. Crosier PS, Ricciardi ST, Hall LR, et al. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood. 1993;82:1151-1158.
15. Uccini S, Mannarino O, McDowell HP, et al. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Clin Cancer Res. 2005;11:380-389.
16. Montone KT, van Belle P, Elenitsas R, et al. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol. 1997;10:939-944.
17. Raspollini MR, Amunni G, Villanucci A, et al. c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann Oncol. 2004;15:594-597.
18. Ulivi P, Zoli W, Medri L, et al. c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat. 2004;83:33-42.
19. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689-695.
20. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
21. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566-578.
22. Baker DE. Imatinib mesylate. Rev Gastroenterol Disord. 2002;2:75-86.
23. Tarn C, Merkel E, Canutescu AA, et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res. 2005;11:3668-3677.
24. Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess. 2005;9:1-142.
25. US Food and Drug Administration. FDA approves new treatment for gastrointestinal and kidney cancer [press release]. Rockville, MD: FDA; January 26, 2006. Available at: http://www.fda.gov/bbs/topics/news/2006/NEW01302.html. Accessed March 1, 2006.
26. Chhieng DC, Jhala D, Jhala N, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy: a study of 103 cases. Cancer. 2002;96:232-239.
27. Bardales RH, Stelow EB, Mallery S, et al. Review of endoscopic ultrasound-guided fine-needle aspiration cytology. Diagn Cytopathol. 2006;34:140-175.
28. Vander NM III, Eloubeidi MA, Chen VK, et al. Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer. 2004;102:157-163.
29. Stelow EB, Stanley MW, Mallery S, et al. Endoscopic ultrasound-guided fine-needle aspiration findings of gastrointestinal leiomyomas and gastrointestinal stromal tumors. Am J Clin Pathol. 2003;119:703-708.
30. Carvalho I, Milanezi F, Martins A, et al. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005;7:R788-R795.
31. Reis RM, Martins A, Ribeiro SA, et al. Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas. Cell Oncol. 2005;27:319-326.
32. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
33. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751-1757.
34. Morey AL, Wanigesekera GD, Hawkins NJ, et al. C-kit mutations in gastrointestinal stromal tumours. Pathology. 2002;34:315-319.
35. Wasag B, Debiec-Rychter M, Pauwels P, et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol. 2004;17:889-894.
36. Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer. 2003;106:887-895.
37. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12:1743-1749.
38. Frost MJ, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1:1115-1124.
39. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005;102:11011-11016.
40. Fu K, Eloubeidi MA, Jhala NC, et al. Diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration biopsy: a potential pitfall. Ann Diagn Pathol. 2002;6:294-301.
41. Willmore-Payne C, Layfield LJ, Holden J A. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens. Cancer. 2005;105:165-170.
42. Padilla C, Saez A, Vidal A, et al. Fine-needle aspiration cytology diagnosis of metastatic gastrointestinal stromal tumor in the liver: a report of three cases. Diagn Cytopathol. 2002;27:298-302.